Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genmab | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 113.14B | 18.8x | -1.5 | DKK 1,839 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.5% Upside | Upgrade to Pro+ | |
| Zealand Pharma | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 21.32B | 3.3x | 0 | DKK 299.90 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Gubra AS | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 5.63B | 3.7x | 0 | DKK 344.60 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37% Upside | Upgrade to Pro+ | |
| ViroGates | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 103.03M | -8.3x | -0.25 | DKK 11.10 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Strategic Partners AS | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 26.90M | -30.7x | 0.18 | DKK 645 | 5.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |